Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Crane NXT, Co. finalized the acquisition of Antares Vision S.p.A., a leading company in detection, inspection, and traceability technologies. This acquisition broadens Crane NXT's portfolio, especially targeting the ~$3 billion life sciences and food & beverage sectors. Antares Vision has been delisted from Euronext Milan and is now a wholly owned …
Anterix has entered into a 900 MHz spectrum sale agreement with Texas-New Mexico Power (TNMP) to enable deployment of a mission-critical private wireless network aimed at improving grid reliability and outage response. This collaboration supports TNMP's System Resiliency Plan and aligns with a broader trend of Texas utilities adopting secure privat…
MiNK Therapeutics announced that an abstract on its investigational allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797, has been accepted for presentation at the 2026 American Thoracic Society International Conference. The presentation will highlight a novel combination immunotherapy approach targeting severe and persistent infect…
Medicus Pharma Ltd. provided clarification on its Phase 2 clinical trial data for SkinJect, a doxorubicin-containing microneedle array for nodular basal cell carcinoma treatment. The company emphasized the therapeutic importance of the active drug arms over the device-only arm, highlighting that the 200µg dose cohort demonstrated the most promising…
Dyne Therapeutics announced participation at the 2026 AMCP Conference with presentations on clinical trial data supporting their Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) therapeutics. The company is preparing for potential U.S. launches of DMD treatment next year and DM1 treatment in early 2028, focusing on payer engage…
RenX Enterprises Corp. reported fiscal year 2025 financial results, highlighting $8.2 million in post-acquisition revenue—17% above guidance—after acquiring Resource Group US Holdings LLC. The company completed the buildout of its Myakka City biomass processing facility, initiated deliveries into the premium compost market, retired $11.9 million in…
Brookfield Infrastructure Partners will release its first quarter 2026 results on April 29, 2026, with a conference call and webcast scheduled on the same day. The company operates global infrastructure assets across utilities, transport, midstream, and data sectors, focusing on assets with contracted and regulated revenues to ensure stable cash fl…
Rapport Therapeutics announced it will present new 8-week follow-up data from its Phase 2a trial of RAP-219, a novel targeted treatment for focal onset seizures, at the 2026 American Academy of Neurology Annual Meeting. RAP-219 specifically modulates the TARP-γ8 AMPA receptor subunit, potentially offering improved efficacy and tolerability for neur…
RYTHM, Inc. announced amendments to its trademark and recipe license agreements with Green Thumb Industries, resulting in a fixed annual cash fee of $70 million with escalations tied to the Consumer Price Index. This new structure provides predictability and stability in revenue, supporting RYTHM's Nasdaq listing and strategic market position in th…
Tilray Brands, Inc. reported record third quarter fiscal 2026 results driven by 11% net revenue growth to $207 million and a 6% increase in gross profit to $55 million. The company exhibited strong international cannabis revenue growth of 73% year-over-year, solidifying its leadership in the Canadian cannabis market. The recent acquisition of BrewD…
Macerich, a prominent REIT specializing in retail real estate across key U.S. markets, has scheduled the release of its Q1 2026 earnings report for May 6, 2026, following market close. Management will host a conference call the same day to discuss the results. The company continues to focus on its portfolio and environmental, social, and governance…
Brookfield Renewable, a leading global renewable power and sustainable solutions company, will release its first quarter 2026 results on May 1, 2026, followed by a conference call and webcast to discuss financial results and business initiatives. The company operates a diverse renewable energy portfolio including hydroelectric, wind, solar, and sto…
FitLife Brands announced its Q4 and full-year 2025 financial results highlighting a 73% increase in Q4 revenue and a 26% increase for the full year, largely fueled by the recent acquisition of Irwin Naturals. Despite growth in total and wholesale revenues, gross margins declined due to Irwin's historically lower margins and amortization expenses. N…
Ocular Therapeutix, Inc. announced plans to present new data from their Phase 3 clinical trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration at upcoming scientific conferences in April 2026. The presentations aim to highlight the drug's efficacy and support its therapeutic potential, with sessions scheduled at the Vit-Buckle Society…
BioXcel Therapeutics announced that the FDA has accepted its supplemental New Drug Application for IGALMI® to be used in the at-home setting to acutely treat agitation associated with bipolar disorders or schizophrenia. The FDA set a PDUFA action date of November 14, 2026. This approval could introduce the first FDA-approved at-home treatment for a…
Lightbridge Corporation announced receiving a Notice of Allowance from the USPTO for a new U.S. patent covering its advanced spirally twisted, multi-lobed metallic fuel assemblies designed for pressurized heavy-water reactors including CANDU-type designs. This strengthens their intellectual property portfolio for their advanced nuclear fuel technol…
Eldorado Gold Corporation and Foran Mining Corporation announced upcoming shareholder meetings for approval of a proposed plan of arrangement wherein Eldorado will acquire Foran, making it a wholly-owned subsidiary. The combined entity aims to leverage Eldorado's financial strength and operational platform with Foran's copper growth projects, targe…
Axsome Therapeutics has acquired exclusive global rights to balipodect (TAK-063), a selective PDE10A inhibitor from Takeda. The company plans to develop balipodect for schizophrenia and Tourette syndrome, initiating Phase 3 trial-enabling activities for schizophrenia in 2026. Balipodect represents a potential first-in-class mechanism targeting neur…
B2Gold Corp. has announced the renewal of its normal course issuer bid (NCIB), allowing the company to repurchase up to 132.7 million shares, equivalent to 10% of its public float, over the next 12 months. This move aligns with B2Gold's strategy to return value to shareholders and reflects management's belief that the shares may be undervalued. Sha…
NewGenIVF Group Limited announced the filing of its 2025 annual report on Form 20-F with the SEC. The company operates a diversified business spanning real estate development in the UAE, digital asset and DeFi solutions, and reproductive health services in Asia. The report highlights strategic initiatives across these sectors and discloses associat…
Apollomics Inc., a clinical-stage biopharmaceutical company focused on oncology therapies, announced $2 million unsecured convertible promissory note financing from its CEO. The funds will support clinical development and corporate operations, with conversion linked to a future equity financing event. The financing terms were approved by the indepe…
Tiziana Life Sciences announced positive preclinical results demonstrating that their lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, can reduce neuroinflammation and improve cognition in aging-related models. These results support its potential use in treating neurodegenerative conditions and cognitive decline ass…
Pasithea Therapeutics announced that the FDA has granted Fast Track designation to PAS-004, its next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN). This designation facilitates more frequent communication with the FDA, rolling review processes, and may enable accele…
Ocugen, Inc. announced the early completion of dosing in its Phase 2/3 GARDian3 clinical trial for OCU410ST, a potential first-in-class modifier gene therapy for Stargardt disease. The trial enrolled 63 patients and aims to evaluate efficacy and safety in slowing the progression of this inherited retinal disorder. Interim data is expected in Q3 202…
Descartes Systems Group announced that ER2, an Arizona-based IT asset management company, is utilizing Descartes' Sellercloud platform to unify inventory, warehouse, and shipping operations across eight warehouses. This integration led to a 75% improvement in picking speed, reduced shipping errors, and lower shipping costs, supporting ER2's growth …
